Surgery remains an effective treatment for many types of cancer. Despite advances in surgical techniques, distinguishing malignant from benign tissues is still challenging. In the last years, fluorescence imaging using targeted fluorescent tracers has demonstrated enormous potential to guide preoperative decision-making and personalize surgical treatment. Nanobodies are unique antibody-binding fragments derived from camelid heavy-chain antibodies with excellent properties for rapid and highly specific molecular imaging. In this project, we aim to develop and preclinically validate fluorescently-labeled nanobody-based tracers for image-guided surgery. Hereto, specific nanobodies targeting relevant cancer biomarkers will be generated and validated in preclinical animal models. By the end of the project, we aim to obtain fully in vitro and in vivo characterized nanobody-based fluorescent tracers ready for clinical translation.
- Vrije Universiteit Brussel
- Hernot, Sophie, Supervisor
|Place of Publication||Brussels|
|Publication status||Published - 2023|